Rapid Micro Biosystems Q3 2024 Earnings Update

Rapid Micro Biosystems (ticker: RPID), a leader in automated microbial quality control testing, announced a significant increase in revenue and system placements during its third-quarter earnings call on November 1, 2024. The company reported a record total revenue of $7.6 million for Q3, marking a 24% year-over-year increase and the eighth consecutive quarter of surpassing guidance. Rapid Micro Biosystems also confirmed its full-year revenue forecast of at least $27 million, reflecting the company's steady growth trajectory.

Key Takeaways

• Rapid Micro Biosystems reported a quarterly record revenue of $7.6 million, a 24% increase from the same quarter last year.
• The company placed seven Growth Direct systems in Q3, the highest since Q3 2021, totaling 15 systems for the year.
• Gross margins improved to 8%, a significant rise from -27% in the previous year, due to cost reductions and increased efficiency.
• The net loss narrowed to $11.3 million compared to $13.4 million in Q3 2023.
• Operating expenses are projected to be between $50 million and $51 million for 2024, with a cash burn of about $40 million.
• The company aims for positive cash flow by the end of 2027 without the need for additional financing.

Company Outlook

• Full-year revenue expected to exceed $27 million, indicating at least 20% growth year-over-year.
• Anticipated placement of at least 20 Growth Direct systems by the end of 2024.
• Projected service revenue for Q4 2024 between $2.5 million and $3 million.
• Operating expenses for the full year are estimated to be between $50 million and $51 million.
• The company targets positive cash flow by the end of 2027 without additional external funding.

Bearish Highlights

• Market conditions continue to be cautious, with longer purchasing cycles and increased scrutiny on capital expenditures.

Bullish Highlights

• The company received a multi-system order from a top 20 pharma customer, validating its commercial strategy.
• Strong prospects in the biologics and cell and gene consumables sectors.
• Positive early feedback on the sterility product, with potential incremental revenue contributions in 2025.

Misses

• Despite the improved financials, the company still operates at a net loss, with Q3 2024's loss recorded at $11.3 million.

Q&A Highlights

• The company expressed optimism about the adoption of its sterility product and expects it to contribute to revenue in 2025.
• Gross margins are projected to continue improving, with the possibility of achieving positive margins in Q4.

Rapid Micro Biosystems' CEO, Rob Spignesi, emphasized the effectiveness of their commercial approach, which has been instrumental in securing a multi-system order from a top 20 pharma customer. The company is focused on global pharma, expecting significant contributions from other segments in the future. CFO Sean Wirtjes provided details on the financials, noting the increase in product and service revenue and the decrease in net loss compared to the previous year. The company's financial discipline and operational efficiencies have led to improved gross margins and a reduction in cash burn.

Upcoming Events

Looking ahead, Rapid Micro Biosystems will host the annual Growth Direct Day in the Netherlands to strengthen customer relationships and underscore the platform's value. With a cautious market environment, the company relies on high-return-on-investment projects to maintain momentum. The optimism surrounding the sterility product and the potential for positive margins by Q4 highlight the company's forward-looking strategy.

InvestingPro Insights

Rapid Micro Biosystems' recent financial performance aligns with several key metrics and insights. The company's revenue growth of 29.04% over the last twelve months supports the reported 24% year-over-year increase in Q3 revenue. Despite the positive revenue growth, data reveals that the company is not yet profitable, with a negative gross profit margin of -14.22% over the last twelve months. However, the improvement in gross margins to 8% in Q3 suggests progress towards profitability.

An InvestingPro Tip indicates the company is burning through cash but also holds more cash than debt on its balance sheet, which may provide financial flexibility as it aims for positive cash flow by 2027.

The stock's performance has been strong, with a 59.29% price return over the last three months, reflecting investor optimism about the company's growth prospects and improved financial metrics. For a comprehensive analysis, InvestingPro offers additional insights into the company's financial health and market position.

Conclusion

Rapid Micro Biosystems showcases a strong performance and outlines a path towards profitability and sustainable growth, despite existing market challenges.